Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Keratosis, Actinic 6Neoplasms 5Melanoma 3Warts 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hyperthermia 2Hematologic Neoplasms 2Hemangioma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Intraepithelial Lesions 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors Harboring NTRK Fusion 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Polycystic Ovary Syndrome 1Pituitary Neoplasms 1Pelvic Neoplasms 1Pain 1Ovarian Neoplasms 1Obesity 1Nonmelanoma Skin Cancers 1Mucositis 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Lymphoma, T-Cell 1Lung Neoplasms 1

Interventions

Metformin 3fluorodopa F 18 2Clomiphene 2pasireotide 1dapagliflozin 1amino-acid, glucose, and electrolyte solution 1Surveys and Questionnaires 1Sugars 1Solutions 1Saline Solution 1Pioglitazone 1Insulin 1Injections 1Diazoxide 1Amino Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hyperinsulinism × Solutions × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡